Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The goal of the Lymphoma Program's clinical research effort is to make the treatment of lymphoid malignancies more effective and specific, while also less toxic. Toward that goal, the program makes promising new therapies available to patients with a variety of lymphoid malignancies, in a carefully monitored setting, through clinical trials.
Current research focuses on targeting tumors with drugs directed against specific molecular targets in lymphoid malignancies, or with antibodies reactive against tumor cell surface proteins, alone or linked to radionucleotides. Another target of therapy is the tumor's "microenvironment" using inhibitors of angiogenesis (new blood vessel development) and stimulators of the immune response. Our team is also leading several clinical trials of CAR T-cell therapy for lymphoma.
Many members of the clinical research team also have active programs of laboratory-based investigation in lymphoid malignancies. Researchers work closely with other scientists within Harvard Medical School-affiliated institutions.
Trial 22-248: A phase 1 multicenter study of ruxolitinib and duvelisib in relapsed or refractory T- or NK-cell lymphomasPrincipal Investigator: Eric Jacobsen, MD
Trial 21-204: A phase 2 multi-cohort trial of ipilimumab with and without nivolumab in patients with relapsed/refractory classic Hodgkin lymphoma Principal Investigator: Reed Merryman, MD
Trial 21-040: A phase 1/2 study of acalabrutinib, venetoclax, and obinutuzumab (AVO) in patients with relapsed/refractory and previously untreated mantle call lymphomaPrincipal Investigator: Austin Kim, MD
Trial 20-069: A phase 1/2 study of copanlisib plus venetoclax for the treatment of relapsed/refractory diffuse large B-cell lymphomaPrincipal Investigator: Jennifer Crombie, MD
Trial 19-113: A phase 2 frontline PET/CT-2 response adapted brentuximab vedotin and nivolumab incorporated and radiation free management of early stage classical Hodgkin lymphomaPrincipal Investigator: Ann LaCasce, MD, MMSc
New Patient Appointments 877-442-3324
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)